Neurologix to showcase novel gene transfer approach to Parkinson’s disease

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Sep 15 2009

Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that the company will showcase its novel gene transfer approach to Parkinson’s disease and other serious brain and central nervous system diseases at the BioPharm America partnering conference being held in San Francisco, CA on September 17 – 18. John Mordock, Neurologix President and Chief Executive Officer, will discuss the company’s technology, ongoing Phase 2 trial in advanced Parkinson’s disease and other development programs from 4:15 – 4:30 on Thursday September 17 in Salon 14 at the Marriott San Francisco.

Source:

http://www.neurologix.net/

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

ANU scientists uncover gene mutation driving psoriasis and psoriatic arthritis
Study identifies genetic variants with profound impact on obesity risk
MIT researchers develop new method to quickly screen cancer-associated genetic mutations
Gene defect associated with argininosuccinic aciduria corrected using CRISPR-Cas9 technique
Investigational gene therapy shows promise for rare childhood neurodegenerative disease
Rare variants in the YKT6 gene cause new neurological disorder, study finds
Lurie Children's Hospital administers first gene therapy for Duchenne muscular dystrophy in Illinois
MUTYH gene mutation linked to increased risk of various solid tumors

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Novel genetic link uncovered in generalized pustular psoriasis